Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD-18 in Healthy Subjects With Overweight or Obesity
NCT06739707Phase 1Suspended
- Sponsor
- Cohen Global
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of MD-18 in obesity (7 cohorts), sponsored by Cohen Global. Primary endpoints: Adverse Events at 8 months, Body Temperature at Day 92 and 10 more. Started Jan 2025; status: suspended.
02
Drugs
MD-18
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06739707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739707.